Pyrophosphate arthropathy includes pseudogout and other calcium pyrophosphate dihydrate (CPPD)-crystal-related arthropathies. These are common conditions that present particular management problems in clinical practice as they often affect older patients with multiple medical comorbidities. In this talk, current understanding of the pathogenesis of pyrophosphate arthropathy is presented. Recent novel insights into the pathogenesis of crystal-induced joint inflammation and subsequent joint degeneration are discussed. The epidemiology, metabolic and endocrine disease associations, and routine investigations used in the diagnostic workup are briefly reviewed. Current treatment approaches that are mainly directed at relieving the symptoms of joint inflammation are outlined. Unlike gout, there are no agents available that have been shown to decrease crystal load in CPPD-related joint disease. The potential of colchicine as a prophylactic agent in managing recurrent attacks and the likely mechanisms of its effects on the NACHT, LRR and PYD domain-containing protein 3 (NALP-3) inflammasome of the innate immune system are highlighted. The use of agents that directly target the inflammasome, in particular drugs which inhibit the IL-1 pathway, in the treatment of severe, refractory pseudogout is discussed Disclosures: The author has declared no conflicts of interest.
I3. GENETIC AND ENVIRONMENTAL RISK FOR HYPERURICAEMIA AND GOUT
Michael Doherty 1 1 Academic Rheumatology Clinical Sciences Building, University of Nottingham, Nottingham, UK Gout is the most common chronic inflammatory arthritis and its incidence and prevalence continue to rise in many parts of the world. Gout is a common complex disorder with multiple genetic, constitutional and environmental risk factors, the majority of which lead to persistent elevation of uric acid above the saturation point for urate crystal formation. This presentation will review data relating to: the heritability of gout; individual genetic risk factors (which predominantly involve renal excretion of uric acid); constitutional risk factors (male gender, ageing, OA); metabolic syndrome-obesity, hypertension, hyperlipidaemia, insulin resistance (each of which independently elevate uric acid levels); nutritional risk factors; and risk factors relating to renal impairment, drugs and extrinsic toxins. Risk factors for provocation of acute attacks will also be considered. Disclosures: M.D., Ipsen, Menarini, Savient, Ardea Biosciences, Novartis-Ad hoc Advisory Board.
FASTER, SAFER, CHEAPER? ADVANCES IN ORTHOPAEDIC SCIENCE I4. FAST-TRACK HIP AND KNEE ARTHROPLASTY: CURRENT STATUS AND FUTURE CHALLENGES
Henrik Husted 1 1 Arthroplasty and Spine Section, Hvidovre University Hospital, Hvidovre, Denmark
Fast-track THA and TKA is a dynamic process combining clinical and logistical enhancements to ensure the best outcome for all patients regarding faster early functional recovery and reduced morbidity. Focus is on reducing convalescence by ensuring a smooth pathway with the best available clinical treatment from admission to discharge-and beyond. Main focus areas include pain treatment, mobilization, organizational aspects, traditions, and care principles. Outcome is typically evaluated as: (i) length of stay in hospital (LOS), patient satisfaction, and reduced convalescence in the form of earlier achievement of functional milestones; (ii) safety aspects (reduced morbidity and mortality in the form of complications and readmissions in general and dislocations/manipulations in specific); (iii) feasibility (can the track be applied to other subgroups of patients, i.e. bilaterals or revisions?); and (iv) economic savings. Favourable outcomes regarding all these parameters have been documented for fast-track THA and TKA. This presentation will highlight the current status of fasttrack THA and TKA with a kaleidoscopic overview of the documented best available treatment on the main focus areas as well as address future challenges for improving even further-which includes a revision of traditions and answering of the question: Why is the patient in hospital today? LOS is now 1-2 days for unselected patients in leading departments with few readmissions, high patient satisfaction and economic savings. In Denmark, the nationwide median LOS is now 4 days and improved logistic features include homogeneous entities, regular staff, high level of continuity, preoperative information including intended LOS, admission on the day of surgery and functional discharge criteria. The improved clinical features include both intraoperative (spinal anaesthesia, local infiltration analgesia (LIA), plans for fluid therapy, small standard incisions, no drains, compression bandages and cooling) and postoperative (deep venous thrombosis prophylaxis starting 6-8 h postoperatively, multimodal opioidsparing analgesia, early mobilization and discharge when functional criteria are met) facilitating early rehabilitation and discharge. Future challenges include identification of high-pain responders to improve multimodal pain treatment; identification of high-risk patients regarding complications in fast-track set-ups; how to reduce postoperative cognitive dysfunction; how to reduce orthostatic intolerance; and when how and to whom to initiate and give rehabilitation. Disclosures: H.H., Biomet-Consultant, Rapid Recovery Consultation Fees.
I5. LESSONS FROM THE NATIONAL JOINT REGISTRY AND PATIENT REPORTED OUTCOME MEASURES (PROMS)
Simon Jameson 1,2 1 Trauma and Orthopaedics, James Cook University Hospital, Middlesbrough and 2 School for Medicine and Health, Durham University, Stockton-on-Tees, UK Around 160 000 hip and knee replacements are carried out annually in England and Wales. The National Joint Registry has collected information on joint replacement patients, the implants used, and the surgeons and hospitals performing these operations since 2003, and is currently the largest implant registry. There are many implant options available and national implant expenditure is vast. Revising implants that have failed carries the risk of higher morbidity and poorer function compared with primary procedures, and is costly to healthcare providers. Thus, performing the most appropriate primary procedure to reduce this revision burden is of paramount importance.
Registry analyses allow long-term comparisons across large numbers of implants, and between patient groups, hospitals and surgeons where randomized trials are not feasible. More emphasis is now placed on these large non-randomized observational studies as evidence for best practice. The key areas that required examination were: the most appropriate implant in younger patients (including the role of unicondylar knee replacements and hip resurfacing), the justification for costly implant technology in older patients and the use of patient-reported outcome measures following joint replacement. The lessons learned from these analyses will be discussed. Disclosures: The author has declared no conflicts of interest. I will use my experience of over 20 years as an oncologist to show how a clinical trial culture can be developed in a busy department. The developments in oncology over those 20 years have been significant and analogous to the situation that rheumatology is in as a specialty. The trial culture has many benefits, and the most important is the patient outcome which I will illustrate with examples from my own practice. It is 30 years since Tamoxifen was shown to be of benefit to breast cancer patients, but even recently trials such as ATLAS have revealed an additional 3% mortality benefit which will save over 1200 lives per year in the UK. Involvement in the initial trials of the monoclonal antibody trastuzumab have led to large mortality benefits and the patients being discharged now at 10 years follow-up for an aggressive breast cancer can be told with a high degree of confidence about their chances of cure.
I6. INSIGHTS INTO ARTICULAR RESURFACING AND WHAT HAPPENED WITH METAL ON METAL IMPLANTS
There are indirect benefits with trial involvement, an example being the external quality assurance programme and team that comes with the national radiotherapy trials where technical advances are put into place. Our department welcomes this external input and helps drive forward our desire to improve the service we provide for our patients; it breeds excellence.
Patients derive not only better outcomes from involvement with treatments that may become standard of care in the future but also security from being managed by a team that is perceived (and is) at the cutting edge of medicine. Disclosures: The author has declared no conflicts of interest.
I8. HOW RESEARCH CHANGED MY LIFE
Ailsa Bosworth 1 1 National Rheumatoid Arthritis Society, Maidenhead, Berkshire, UK Taking part in a trial at Guys in 2000 for a new anti-TNF drug that was unlicensed in the UK at the time, changed my life in more ways than one. It got my disease under control for the first time after 18 years of pretty aggressive disease and led me to start the National Rheumatoid Arthritis Society, a job which I have found more challenging, yet immensely fulfilling than any other job I have ever had.
Being invited to speak at this session has caused me to look at the experience of being on a trial for 4 months and what that meant to me personally, and to examine why people seem to respond well to intensive vs routine care in RA and to consider the importance of the availability of research to all rather than the few from a patient perspective. Disclosures: The author has declared no conflicts of interest.
I9. SHOULD IT BE STANDARD OF CARE TO OFFER ENTRY TO RESEARCH TRIALS AT EACH THERAPEUTIC DECISION STAGE OF THE PATIENT JOURNEY?
Maya Buch 1 1 University of Leeds, Leeds, UK
The management paradigm and therapeutic landscape of rheumatoid arthritis (RA) has advanced greatly over the last decade. Whilst patients have benefitted markedly with more targeted strategies and the availability of highly effective therapies, our goals of treatment continue to evolve. There therefore remains a continued need to evaluate new treatment approaches as well as new therapies under development. Clinical trials remain the cornerstone for effective evaluation of treatments. Current and future ambitions on the management of RA include the identification of the right treatment for the right patient at the right time. For such a treatment goal to be realized, it is crucial that at every decision-making time point, patients are considered for clinical research studies. This talk will argue the case that to ensure the successful delivery of clinical studies, needed for optimal evidence-based management, clinical research should become a standard of care in a patient's journey. Disclosures: M.B., Abbott, BMS, Roche, UCB-Honoraria, PfizerGrant, Honoraria. It is apparent that recruitment of patients from busy clinical units as well as from established research centres will be required for future high quality clinical research studies. Evidence exists that when there is a vibrant healthy relationship between research and clinical services, rheumatology departments provide a higher quality of patient care and outcomes and the relevant research output is high. Unfortunately this symbiosis is not currently promoted by the market share evolving economy and rigid frameworks are being imposed on academic and health service institutions. A depth of knowledge, broad experience, thoughtfulness, confidence and critical thinking are key foundations for producing a good clinician. These attributes are fundamental for producing a good researcher. Unfortunately, academic/clinical polarization has resulted in an organizational gap into which clinical researchers fall and their strengths are perceived as weaknesses by the purists at the extremes. The recent introduction of national RA guidelines and standards through NICE and other organizations such as BSR, together with development of outcome measures, will facilitate production of quality data not only for research but also for routine clinical purposes, audit, commissioning and revalidation. There are increasing opportunities for collaborative research through patient data entry into CLRN-linked studies, the BSR Biologic Registers and development of the ARUK INBANK project. However the increasing pressures on time and finite resources in rheumatology clinics, especially those without a track record of research, may limit the extent of research activity in many units. Auditing involvement in research may therefore be controversial and development of appropriate standards challenging. Disclosures: The authors have declared no conflicts of interest. Background: Professionals are increasingly encouraged to deliver care for patients with long-term conditions such as arthritis in line with the principles of the Chronic Care Model. The aim is to ensure a coordinated and effective collaboration with patients and encourage effective self-management.
I10. RESEARCH OPPORTUNITIES FOR RA PATIENTS, THEIR RHEUMATOLOGISTS AND THEIR AHPS, INCLUDING ECONOMIC ASPECTS

Deborah Symmons
BHPR: THE EXPERIENCE OF LIVING WITH MUSCULOSKELETAL PROBLEMS AND OTHER CONDITIONS I12. MULTIMORBIDITY IN PATIENTS WITH ARTHRITIS: EXPERIENCE OF CARE AND SELF-MANAGEMENT
However, multimorbidity is increasingly common, especially in older patients and those living in deprived areas. The presence of more than one long-term condition potentially has impacts on the delivery of health care, and on the ability of patients to self-manage outside the context of routine services. However, research is only beginning to identify the challenges posed by multimorbidity. We present data from a cohort of patients with arthritis and other conditions to explore their experience of care, and their reports of self-management. Methods: We surveyed respondents with a range of long-term conditions in general practices in two areas of the UK. We conducted a comprehensive assessment of their demographic and clinical characteristics, their experience of the delivery and organization of care (through the PACIC measure) and their self-reported selfmanagement. Results: In the cohort of 2439 patients with long-term conditions, 33% self-reported arthritis. The number of comorbid conditions reported by these patients ranged from 1 to 12, with a mean of 4, and 29% of patients reported clinically significant levels of depression symptoms.
In terms of their experience of care for their long-term conditions, only around half of patients reported being given choices about treatment, being asked about problems with medicines or their effects, being asked about their goals for treatment, or being given a copy of a treatment plan. Few reported being asked about how their arthritis affects their life or being contacted after visits to assess progress.
In terms of the effects of multimorbidity, 11% reported being overwhelmed by care of one medical condition, such that it made it difficult to care for other conditions, and 7% reported that they received conflicting advice about the care of different conditions. Conclusions: Care for patients with multimorbidity raises many challenges. Data from the survey suggest that much of the care delivered to patients with arthritis is not experienced as being in line with current best practice. A minority of patients also report additional complications associated with multimorbidity. We shall present additional analyses at the conference to build on these initial findings. Disclosures: The author has declared no conflicts of interest. Background: The number of people living with more than one chronic illness (multimorbidity) is increasing. People living with multimorbidity are likely to be active participants in the management and decision making processes around their own conditions. However, emerging evidence suggests that individual patient priorities and decision making processes in relation to multimorbidity are complex. Patients' social networks-family, friends, and work colleagueshave been identified as an important factor in shaping the ways that patients live with and manage chronic illness. Social networks are understood as a source of social resources and are increasingly recognized in emerging models of healthcare. This study addresses the patient experience of living with both OA and cardiovascular disease (CVD); in particular, it addresses the role of patients' social networks in relation to various aspects of illness self-management. Methods: The study sample was drawn from an on-going cohort study into OA/CVD comorbidity. Study participants have a diagnosis of both OA and CVD (all participants have further additional conditions). Indepth qualitative interviews were conducted at multiple time points. Interviews focused upon issues relating to living with and managing concurrent conditions, and the role that participants' social networks played in shaping these experiences. Results: Social networks were found to be a key factor in patients' experiences of multimorbidity. Social networks were an important source of social support-including health information, practical, and emotional support-and played a key role in how patients understand their illnesses. Patients' social networks also influenced the ways in which patients prioritized and managed concurrent conditions, for example, in relation to how they managed polypharmacy and navigated services. However, there were also examples where social networks had a negative affect on how multimorbidity was experienced, for example, some participants spoke of disagreements with their significant others in relation to how their illnesses should be managed. Conclusions: The patient experience of living with and managing multimorbidity is often highly complex. Patients with multimorbidity routinely draw upon their social network as a source of support and advice. It may be useful to consider issues around the management of multimorbidity in the context of patients' inter-personal social relationships. Disclosures: The authors have declared no conflicts of interest. Background: OA is common amongst older adults. The prevalence of many other conditions however also rises with age, and consequently many OA patients also have co-existing chronic conditions or comorbidities. Managing such patients can be difficult given that evidence-based diagnostic and treatment strategies generally overlook the issue of comorbidity. The mismatch, between care delivery and patient need, can therefore lead to difficulties in management and resource allocation (e.g. time) for both patients and clinicians. One potential area of contention is the issue of congruence between clinician and patient condition priorities. A lack of agreement between clinician and patient priorities can impact on the clinician-patient relationship, treatment concordance and potentially health outcomes. Studies have suggested that patients with OA may prioritize comorbidities over their OA, but until now, no explicit systematic exploration of OA patients' priorities in relation to comorbidities existed. This work explores how patients prioritize OA amongst their conditions, what factors underlie this prioritization and whether and why these priorities change over time. Methods: A secondary analysis of qualitative data was performed utilizing four existing datasets collated from the multi-centre research team involved. Purposive sampling provided a sample of 30 participants who all had OA and comorbidities. The research team collectively coded and analysed the data thematically. Results: Three groups of patient emerged from the analysis. The two smaller groups had stable priorities (where OA was or was not prioritized) and illustrated the importance of factors such as personal social context and the specific nature of the comorbid conditions. The third and largest group reported priorities that shifted over time. Shifting appeared to be influenced by participants' perceptions of control and/or interactions with clinical professionals, and could have important consequences for self-management behaviour. Conclusions: We emphasize the importance of acknowledging changing priorities in the illness experience of comorbid OA patients and the need for appreciation by clinicians that their priorities may not be the same as the patient's. We advocate patient-centred models of care within a more integrated system structure, as well as regular assessment of mutual patient-clinician priority interpretations. Such actions may result in more effective clinical encounters and ultimately, optimize patient outcomes. Non-adherence to medical treatment is widespread in patients with rheumatological conditions and across all major health problems. Although a wide range of interventions have been developed to target different aspects of non-adherence, they have not been very successful in providing sustained improvements. This presentation will mainly focus on the extent to which patients' beliefs about their illness and treatment explain why they frequently fail to adhere. It will begin with a more general overview of the nature and causes of adherence failure and, using the distinction between unintentional and intentional types of non-adherence, a range of psychological determinants will be examined. The main focus of the talk will be on the role of illness and treatment beliefs as key determinants of intentional nonadherence, and Leventhal's self-regulation model will provide the theoretical framework for this. In the final part of the talk, examples will be provided of successful intervention studies together with a discussion of key issues for future research. Disclosures: J.W., Atlantis Healthcare-Part-time Contract.
I13. THE ROLE OF PATIENTS' SOCIAL NETWORKS IN SHAPING THE EXPERIENCE OF MUSCULOSKELETAL CONDITIONS IN MULTIMORBIDITY
I14. PATIENT PRIORITIES IN OSTEOARTHRITIS AND COMORBID CONDITIONS
I16. ADHERENCE AND ADAPTATION: TARGETING BELIEFS AND BEHAVIOUR TO OPTIMIZE SELF-MANAGEMENT
Lis Cordingley 1 1 University of Manchester, Manchester, UK
In their 2004 editorial Kravitz and Melnikow described patient adherence to physicians' treatment recommendations as 'the key mediator between medical practice and patient outcomes (p197). Patient adherence to medication, physiotherapy and lifestyle advice is recognized as low with some leaders in the field suggesting that a degree of non-adherence should be viewed as the norm for most longterm conditions. Non-adherence covers a range of behaviours including incorrect dosage, incorrect timing, non-attendance at clinic, not undertaking recommended exercises and not following health behaviour advice such as smoking cessation. Recent studies of patients with rheumatoid arthritis have reported rates of medication non-adherence of around a third, although estimates vary according to the measure of adherence used.
Provision of information alone rarely leads to changes in behaviour and interventions based upon increasing knowledge have had little impact upon adherence rates. In line with the development of patientcentred practice use of the term adherence has overtaken compliance, and communication skills have been cited as key to improving medication self-management. However, this talk will present evidence indicating that theory-based approaches to consultations that target patient beliefs and behaviour are more likely to improve patient motivation and outcome than communication skills alone.
The introduction of new therapies including anti-TNF therapy for inflammatory arthritis are seen as a significant advance in treatment, however, they may also bring additional challenges to patients such as adapting to new modes of delivery or new concerns about the nature of the medication itself. Moreover, a decision to step-up treatment with more powerful therapies may also act as an unwelcome reminder to the patient of the severity of their condition or an indication that prior treatments have failed. Studies are needed to identify the challenges faced by patients using new therapies. Some new findings from a prospective study investigating the influence of demographic and psychological factors on adherence to anti-TNF medication by patients newly started on treatment will be presented.
Patients face a number of adaptive challenges to living with longterm inflammatory conditions and these can have an impact on selfmanagement, particularly in the area of treatment adherence. Attending to broader patient perspectives and viewing non-adherence as an anticipated and understandable behavioural response enables health professionals to open up discussions about factors that influence medication use and to devise effective systems to optimize patient self-management. Disclosures: The author has declared no conflicts of interest. Adhering to a recommended treatment or to advice for self-managing a chronic condition usually requires the person to alter their behaviour in some way, e.g. to take a new tablet or to do some exercise that they have not previously done.
I17. THE CLINICAL APPLICATION OF BEHAVIOUR CHANGE STRATEGIES TO FACILITATE ADHERENCE TO TREATMENT
Sarah Dean
Michie and colleagues (2011) have collated a list of evidence based techniques that can be used by health professionals to promote this behaviour change. Their behaviour change technique (BCT) taxonomy lists 93 strategies. The taxonomy is used to identify and describe in a standardized way, the active behaviour change components of interventions designed for treating a wide range of health conditions. These BCTs can be used to help design interventions but also have utility for direct clinical application.
In this presentation the examples will focus on some of the BCTs that can be usefully applied in a musculoskeletal rehabilitation setting, particularly for promoting adherence to therapeutic exercise, for example goal setting and action planning. Disclosures: The author has declared no conflicts of interest. 2 ) but become less useful as evidence of renal bone disease develops. In the later stages of renal failure osteoporosis is often accompanied by secondary hyperparathyroidism and various forms of renal bone disease (CKD-MBD: chronic kidney disease-mineral and bone disorder).
In mild to moderate CKD (Stage 3) treatment centres around assessing fracture risk, correcting vitamin D insufficiency and being careful with bisphosphonates as GFR falls below 40 ml/min. In mild hyperparathyroidism such as is found in early CKD there is preservation of cancellous bone but loss of cortical bone due to increased endosteal resorption. This cortical thinning has an adverse effect on bone strength but may be obscured by preserved trabecular bone and may explain why fracture risk is increased in these patients despite minimal reduction in BMD assessed by DXA. At this stage of CKD high resolution peripheral quantitative computed tomography (HRpQCT) tends to show evidence of early trabecular loss with a reduction in trabecular number and an increase in trabecular separation but no change in thickness.
As end stage renal disease approaches (CKD 4-5D) it becomes increasingly important, but difficult, to differentiate osteoporosis from renal bone disease. Densitometry (DXA) is unable to separate these components and although many patients will experience a progressive decline in both lumbar spine and femoral neck BMD these changes do not correlate with the major changes in PTH, FGF 23 or calcitriol. For these reasons it is often impossible to predict the type of underlying bone disease and other techniques such as HRpQCT have been used either to evaluate ex-vivo bone biopsies or to study bone in vivo.
In end stage renal disease there are few studies of the relationship between BMD, fracture risk and the response to treatment so that the strength of clinical evidence is weak and the quality of studies is low. Renal transplant bone disease has a multifactorial aetiology where there is a high risk of fractures but no data relating BMD to fracture risk. At a clinical level it is difficult to identify those patients who may benefit from treatment and there are no randomized trials of bone specific treatment. Extrapolation from non-renal transplant patients may not be valid and the situation is confounded by the use of immunosuppression and glucocorticoids. Disclosures: The author has declared no conflicts of interest.
I19. SARCOPENIA: IS IT A DISEASE AND CAN IT BE TREATED?
Avan Aihie Sayer 1 1 MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK Sarcopenia is the loss of skeletal muscle mass and function with age. There is growing consensus about how it should be defined and it has become clear that it is common in both older women and men. It has serious health consequences in terms of disability, morbidity and mortality as well as significant healthcare costs.
Adult influences on sarcopenia include levels of physical activity, nutritional intake, setting of the immune-endocrine axis and genetic variation. However there remains considerable unexplained variation in muscle mass and strength amongst older people and this has led to an innovative lifecourse approach to sarcopenia. This involves focus on the determinants of peak muscle mass and strength attained in early adulthood as well as consideration of factors modifying decline in later life.
The evidence for treatment with resistance exercise is well established and the additional benefit of nutritional supplementation is currently being studied. Drug discovery is also a fertile area and although no agents are currently licensed in the UK, there is interest in whether established drugs with other indications could have a place. Although interventions for sarcopenia to date have generally been targeted at the later stages of life, there is recognition that modifying lifestyle earlier could have benefits for ageing skeletal muscle. Disclosures: A.S., Abbott Nutrition, Servier-Honoraria.
I20. BISPHOSPHONATE THERAPY: WHAT IS THE OPTIMAL DURATION?
Juliet Compston 1 1 Department of Medicine, University of Cambridge, Cambridge, UK Bisphosphonates are the most widely used pharmacological intervention to reduce fracture risk in postmenopausal women and older men at increased risk of fracture. Because of the unique pharmacokinetics of bisphosphonates and, in particular, their long retention time in bone, it is possible that beneficial effects on fracture risk may persist for some time after treatment is stopped. The possible association between bisphosphonate therapy and two rare but serious conditions, namely osteonecrosis of the jaw (ONJ) and atypical femoral fractures, coupled with the prolonged action of bisphosphonates, has raised questions about the optimal duration of therapy. In particular, the issue arises of whether some patients should be given a drug holiday, followed after a period of time by resumption of treatment.
In deciding the optimal duration of therapy, the benefits and risks of both continuation and discontinuation must be considered. Long-term treatment is associated with fracture reduction but may increase the risk of rare adverse effects such as ONJ and atypical fractures. Discontinuation might reduce the risk of ONJ and atypical fractures but may also be associated with reduced protection against fracture. Following withdrawal of bisphosphonate therapy the rate of offset of efficacy varies, being most rapid with risedronate, intermediate for alendronate and longest for zoledronic acid. Post-hoc analysis of Phase 3 trials suggests that women with a low femoral BMD and/or a vertebral fracture at baseline may be at increased risk of fracture if therapy is discontinued For alendronate and risedronate, an initial 5-year period of treatment can be advised, with assessment of the need for further treatment at the end of that time based on fracture history, age and BMD. If treatment is stopped, reassessment of risk should be performed after 2-3 years for alendronate, but at 1 year for risedronate. In patients treated with zoledronic acid, an initial treatment period of 3 years appears to be sufficient, with reassessment of the need for further treatment after 3 years. Nevertheless, the strength of evidence for fracture reduction in high-risk patients treated with bisphosphonates and the rarity of long-term adverse effects emphasise the importance of continuing therapy long-term in individuals who remain at high risk of fracture. Rituximab is a human/mouse chimeric monoclonal antibody which targets CD20 positive B lymphocytes. The ANCA associated vasculitides (AAV) are a group of conditions which predominantly affect small and medium sized vessels. They are now termed granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The untreated prognosis of these conditions is poor and the median survival of untreated GPA in one series has been 5 months. Pulsed or continuous cyclophosphamide induces remission in 90% of patients with AAV, but with the risk of treatment associated morbidity and damage.
Since the first case report of the use of rituximab in a patient with relapsing GPA in 2001, there have been several case reports, open label studies, two randomized controlled trials and at least two sets of published recommendations advocating the use of rituximab in a subsection of patients with AAV. The two RCTs (RAVE and RITUXVAS) demonstrated non-inferiority of rituximab to pulsed cyclophosphamide in inducing remission in patients with AAV. In RAVE, 197 patients with GPA or MPA were randomized to rituximab or cyclophosphamide. 64% of patients in the rituximab arm vs 53% of patients in the control group achieved the primary end-point of remission without steroids at 6 months (P < 0.001). In RITUXVAS, 44 patients with renal AAV were randomized to rituximab or cyclophosphamide arms. 76% in the rituximab arm vs 82% in the cyclophosphamide arm achieved the primary end-point of sustained remission at 12 months (P ¼ 0.68). Post-hoc analysis of 101 patients with relapsing disease in RAVE, 67% of rituximab treated patients vs 42% or cyclophosphamide treated patients achieved the primary end-point (P ¼ 0.01) suggesting that rituximab may be superior to cyclophosphamide for treating relapsing GPA and MPA. Both trials hoped to demonstrate non-inferiority with the presumption that a better adverse event profile will make rituximab a better option for remission induction therapy. But there were no differences in the side effect profile between the control and the experimental arms in both RCTs.
There remain several questions about the position of rituximab in treating AAV. The initial treatment regimen in the clinical trials has been 375 mg/m 2 x 4 weekly pulses, but the conventional treatment regimen in most rheumatology units has been 1 g x 2 fortnightly pulses. Rituximab has been used with concurrent cyclophosphamide infusions and without it. The role of serial monitoring of ANCA, immunoglobulins, and CD20 cells has not been defined. Pre-emptive treatment with rituximab has been used, but with increasing reports of non-infectious pulmonary toxicity and the risk of hypogammaglobulinaemia, this may not be as safe as initially perceived.
Rituximab has partially fulfilled the aspiration of targeted therapy in AAV, but its positioning in the treatment algorithm needs further definition. Disclosures: C.M., Menarini, Schering-Plough-Speaker Fees. In recent years there has been increasing interest in new biologic therapies for SLE. Open-label studies have emphasized the efficacy of rituximab in refractory SLE patients and there is also emerging evidence that use in early disease may hold promise for tailored steroid-free regimes. A number of clinical trials using biologic agents, including rituximab, have not however achieved their primary endpoint. Aspects of trial design including choice of disease activity instrument, use of concomitant medications and inadequate power may have contributed to these perceived 'failures' nevertheless many valuable lessons have been learned from such trials.
I22. CURRENT AND EMERGING BIOLOGICS IN SLE
Recently belimumab has been successful in two pivotal Phase III trials and has been licensed by the EMEA. These trials employed a novel SLE Responder Index (SRI) derived from a secondary analysis of previous Phase II data. Patients with serologically active disease appear to respond best to this agent and use of belimumab within this subset appears to provide long-term stability of disease. Newer agents in development include drugs that target B-cell depletion or modulation in other ways as well as drugs targeting the IFN pathway.
In the UK two major initiatives are under way that will help improve our understanding and use of these agents. The first is a prospective biologics register for SLE patients, which is already established and seeks to study long-term safety of these agents in SLE. Secondly, two trials of B-cell depletion have been supported by Arthritis Research UK, one examining B-cell depletion in refractory non-renal SLE and the other studying early use of B-cell depletion in LN.
Conclusions: Biologic therapy holds much promise in SLE and as we learn more about the disease and apply the lessons learned from recent trials, we will be in a strong position to further accelerate drug development in SLE. UK rheumatologists can lead the way in this through recruitment to national initiatives such as recently funded clinical trials as well as the ongoing UK-wide safety register. Haematological complications are not uncommon in CTDs. These can vary from easily manageable problems like mild to moderate anaemia and leukopenia to difficult cases of severe thrombocytopenia and multi-vessel thrombosis. Treatment of the severe complications involves multidisciplinary approach. In this regard, the arrival of new biologic agents is very much welcome.
Anti-CD20 therapy with rituximab has been shown to particularly effective in thrombocytopenia associated with rheumatological diseases and may be helpful as an agent with 'multi-system' benefits. Anti-complement therapy with eculizumab has found its way into being a useful modality in refractory catastrophic antiphospholipid syndrome. Since increased tissue factor expression is one of the mechanisms for thrombosis in CTDs, newer agents like dilazep (adenosine uptake inhibitor) and defibrotide (adenosine receptor agonist), in addition to the well-known angiotensin converting enzyme inhibitors, are potential therapies due to their effects on monocyte tissue factor expression. Other attractive approaches in this setting include anti-cytokine therapies with ability to inhibit TNF, interluekin-6 and mitogen-activated protein kinases.
In this context, it is also useful to bear in mind the growing number of reports of the paradoxical induction of autoimmune processes, especially with anti-TNF agents. Disclosures: J.T., Alexion-Honoraria. This presentation will provide the background to the topic of work and musculoskeletal conditions. It will outline the challenges (i.e. size of the problem and reasons for work restriction) and opportunities to reduce the burden of musculoskeletal conditions on work, underlining the importance of a biopsychosocial and inter-disciplinary approach involving interaction between those with a musculoskeletal condition, clinicians, employers and policy makers. Disclosures: The author has declared no conflicts of interest. The topic of work continues to develop quickly and demands increasing interest from all stakeholders involved in the care of working age patients with musculoskeletal conditions. Work is important for both individuals and society for economic, social and personal reasons. People with arthritis should have the opportunity to remain in employment or change employment appropriately. Some can continue without help; some require adaptation; some could do different jobs and some can't or even shouldn't work. Patients should have choice in this and not feel stigmatized by not working. Once work is lost it ceases to be an ambition. This session aims to (i) facilitate the provision of direction for delegates to improve work participation for people with musculoskeletal conditions and (ii) act as a mechanism to provide feedback to the Department of Work and Pensions on practice and policy issues. First of all, an overview of the challenges and opportunities to manage work participation for people with musculoskeletal conditions will be provided. This will include a summary of the key issues around assessment of work disability, and multidisciplinary approaches to enhancing work participation. The second part of the session will focus on assessment. Most rheumatologists have noticed an increase in requests for support for DWP assessments and appeals. Some case histories will be presented. The Work Capability Assessment (WCA) is based on generic abilities as discussed in the previous presentation. The particular problems related to arthritis are: Pain stiffness and fatigue; effects of malfunction of individual joints and often huge variability with time. Could relating the assessment to more work based abilities perhaps directly relating to the impacts of arthritis produce a better assessment for arthritic patients? Could such an assessment have a role in the routine assessment of patients and help keep them in work? What would this look like say for hand function? The final component will allow delegates to participate in an open discussion on points raised within the presentations, or issues from practice. This session follows on from the 2011 BHPR conference symposium 'Improving work participation'; it was apparent that there were a number of delegates, from across the multi-disciplinary team, who came to this session looking for advice on assessing and managing work problems for patients with musculoskeletal conditions. In addition a number of issues from the presentations provoked further audience participation. Disclosures: The authors have declared no conflicts of interest. To provide a coordinated network for early career researchers that facilitates peer group discussion and support from a range of leading academics. This interactive speed-dating session will enable you to meet other researchers with common interests and methods, and begin to build networks for post-doctoral collaborations. The facilitators will give you brief guidance on how to effectively communicate your research to others. A networking database will be constructed after the event to facilitate communication among the delegates that attended. SLE has been a challenge to physicians and patients for over 100 years. The disease is more common than many people realize, especially in those of African descent, and can be difficult to diagnose due to its varied presentations. Although now recognized as a condition that affects about 1 in 2000 women in the UK, it is rarer in men and may appear to be a more severe disease in men than in women, as milder cases may go undetected. Involvement of the kidneys is more common in those of African origin. This is asymptomatic and will be missed if not actively sought. Although LN used to have a poor prognosis, with early detection and appropriate treatment the outcome is now much better, particularly with improvements in the management of comorbidities and an increasing number of drugs available for the treatment of refractory cases. Much work has been done on developing better methods for the classification of lupus, the assessment of disease activity in all systems including neurological, gastrointestinal, ophthalmic and renal, as well as identifying and reducing the risk of chronic damage due to the disease and its treatment. In addition, the multitude of effects of the disease on the lives of patients have been documented using quality of life instruments and on line surveys, to supplement comments made by patients in the clinic. As a result of these activities there is better methodology for assessing the benefits of new therapies than were available 25 years ago. However optimal outcome measures for clinical trials in lupus have yet to be confirmed and it is likely that multiple methods of ascertainment will continue to be necessary for demonstrating efficacy and safety in this complex disease, as are required to identify patients with the disease in epidemiological surveys. Meanwhile a number of exciting clinical trials are in progress for renal and non-renal lupus. With better disease control, an increasing number of women with lupus are keen to undertake pregnancy although this used to be considered too dangerous to recommend. Fortunately we have analysed long term data on the outcome of children born to mothers with lupus, as it is critical that they receive pre-pregnancy counselling about the possible risks and likely outcomes of pregnancy due to the disease and its treatment in their individual case. It is important that lupus patients are on optimal therapy and that they are managed by a multidisciplinary team before and during pregnancy. Disclosures: The authors have declared no conflicts of interest.
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